You might also like
Philip Morris International Inc. (PMI) is a leading international tobacco company committed to creating a smoke-free future by expanding its portfolio beyond traditional tobacco and nicotine products. The company primarily sells cigarettes and smoke-free products, which include heat-not-burn, e-vapor, and oral nicotine products, as well as wellness and healthcare products through its Vectura Fertin Pharma business . PMI has invested significantly in developing innovative smoke-free products, with brands like IQOS and ZYN leading their smoke-free portfolio . The company's operations are organized into several geographical segments, focusing on different regions worldwide .
- Smoke-Free Products - Includes heat-not-burn, e-vapor, and oral nicotine products, with leading brands such as IQOS and ZYN driving the company's transition to a smoke-free future.
- IQOS - A heat-not-burn product designed to provide a smoke-free alternative to traditional cigarettes.
- ZYN - An oral nicotine product offering a smoke-free experience.
- Wellness and Healthcare - Focuses on inhaled therapeutics and oral delivery systems through the Vectura Fertin Pharma business, expanding PMI's reach beyond traditional tobacco products.
- Combustible Tobacco Products - Comprises traditional cigarettes and other tobacco products, continuing to contribute to the company's revenue.
- Geographical Segments - Organized into Europe, South and Southeast Asia, Commonwealth of Independent States, Middle East and Africa (SSEA, CIS & MEA), East Asia, Australia, and PMI Duty Free (EA, AU & PMI DF), and the Americas, allowing PMI to cater to diverse markets worldwide.
-
One of your peers highlighted that in Europe, vapor is seeing greater success in fully converting smokers than heated tobacco; what are your latest thoughts on this topic, and are you seeing an acceleration in vapor adoption as you roll out VEEV in several markets?
-
Regarding the illicit nicotine pouches entering the U.S. market that may infringe on your patents, could you expand on what measures you are currently taking or expect to take, and how do you think this will differ from the current environment we see in vapor in the U.S.?
-
Considering your increased pricing guidance of 8% to 9% and yet positive volumes in combustible cigarettes, shouldn't FY '25 also be a strong year for cigarette volumes and pricing internationally, and can you touch on any disruptive excise tax hikes expected in the next few months?
-
It looks like you modestly took down the top end of your potential deleveraging for this year; could you address what drove that, and with sizable maturities over 2025, are you considering pulling some of that refinancing forward into the remainder of this year, given where markets are opportunistically?
-
With the ongoing supply constraints for ZYN in the U.S., what measures are you taking to match consumer demand, and how confident are you in your capacity expansion plans to meet future growth?
Competitors mentioned in the company's latest 10K filing.
- British American Tobacco plc - Competitor in the tobacco industry .
- Japan Tobacco Inc. - Competitor in the tobacco industry .
- Imperial Brands plc - Competitor in the tobacco industry .
- New market entrants - Particularly with respect to innovative products .
- Several regional and local tobacco companies - Competitors in various regions .
- State-owned tobacco enterprises - Principally in Algeria, Egypt, China, Taiwan, Thailand, and Vietnam .
Customer | Relationship | Segment | Details |
---|---|---|---|
Europe Region Distributor | Distributor | Europe | Accounted for 12% in 2023, 13% in 2022, and 13% in 2021Of consolidated net revenues. |
EA, AU & PMI DF Region Distributor | Distributor | East Asia, Australia & PMI Duty Free | Accounted for 11% in 2023, 12% in 2022, and 15% in 2021Of consolidated net revenues. |
Recent developments and announcements about PM.
Financial Actions
Debt Issuance
Philip Morris International Inc. (PMI) has recently entered into a credit agreement for a senior unsecured revolving credit facility amounting to €1.5 billion (approximately $1.6 billion). This agreement, effective from January 29, 2025, involves several lenders with Citibank Europe PLC, UK Branch acting as the facility agent. The facility is set to expire on January 29, 2028, unless extended. The interest rates for borrowings under this facility will be based on prevailing market rates, and the funds are intended for general corporate purposes, including meeting working capital requirements .
This financial obligation could potentially impact PMI's balance sheet by increasing its liabilities due to the borrowed amount. However, as it is a revolving credit facility, PMI has the flexibility to borrow, repay, and reborrow funds as needed, which can aid in managing liquidity and financial health effectively. The agreement includes customary events of default, such as nonpayment of principal or interest, which, if triggered, could lead to the acceleration of outstanding loans and termination of lender commitments .